Activity of oxaliplatin in patients with relapsed and refractory non-Hodgkin lymphoma.

被引：0
|
作者：
Younes, A [1 ]
McLaughlin, P [1 ]
Pro, B [1 ]
Hagemeister, FB [1 ]
Fayad, L [1 ]
Romaguera, J [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4722
引用
收藏
页码：296B / 296B
页数：1
相关论文
共 50 条
  • [11] Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma
    Schmitt, Michael
    Trenschel, Rudolf
    Sayer, Herbert G.
    Schneider, Catarina
    Glass, Aenne
    Hilgendorf, Inken
    Treschl, Anne
    Junghanss, Christian
    Borchert, Kersten
    Koenigsmann, Michael
    Casper, Jochen
    Beelen, Dietrich W.
    Freund, Mathias
    Kahl, Christoph
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) : 773 - 782
  • [12] Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).
    Davids, M.
    Roberts, A.
    Seymour, J.
    Wierda, W.
    Puvvada, S.
    Gressick, L.
    Alter, D.
    Zhou, L.
    Kim, S.
    Verdugo, M.
    Gerecitano, J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 74 - 74
  • [13] Oxaliplatin (LOHP): A new platinum analog active on refractory/relapsed non-Hodgkin's lymphoma
    Germann, N
    Soulie, P
    Brienza, S
    Rotarsky, M
    Emile, JF
    Di Palma, M
    Musset, M
    Reynes, M
    Cvitkovic, E
    Misset, JL
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 110 - 110
  • [14] A bibliometric analysis for relapsed/refractory Non-Hodgkin lymphoma
    Zhang, F. -p.
    Zhao, X. -y.
    Zhou, J.
    Liu, L. -k.
    Bao, J. -z.
    Zhou, Y. -m.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (10) : 3551 - 3561
  • [15] Options: Relapsed and refractory non-Hodgkin's lymphoma
    Friedberg, Jonathan W.
    [J]. CANCER INVESTIGATION, 2007, 25 : 36 - 37
  • [16] ESHAP with rituximab is highly efficacious with durable responses in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Threja, RR
    Venugopal, P
    Gregory, SA
    O'Brien, T
    Bogdanova, E
    [J]. BLOOD, 2005, 106 (11) : 277B - 277B
  • [17] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    [J]. BLOOD, 2000, 96 (11) : 236B - 236B
  • [18] Fludarabine, mitoxantrone and dexametasone in the treatment of relapsed and refractory low-grade non-Hodgkin lymphoma.
    Sawczuk-Chabin, J
    Kalinka, E
    Centkowski, P
    Budziszewska, K
    Ceglarek, B
    Najda, J
    Blasinska-Morawiec, M
    Sulek, K
    Holowiecki, J
    Konopka, L
    Warzocha, K
    [J]. BLOOD, 2005, 106 (11) : 265B - 265B
  • [19] ETHNICITY SENSITIVITY ASSESSMENT OF POLATUZUMAB VEDOTIN PHARMACOKINETICS IN RELAPSED-REFRACTORY NON-HODGKIN LYMPHOMA.
    Shi, R.
    Lu, T.
    Ding, H.
    Saito, T.
    Gibiansky, L.
    Agarwal, P.
    Li, X.
    Jin, J. Y.
    Girish, S.
    Miles, D.
    Li, C.
    Lu, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S71 - S71
  • [20] Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma
    Oki, Y
    McLaughlin, P
    Pro, B
    Hagemeister, FB
    Bleyer, A
    Loyer, E
    Younes, A
    [J]. CANCER, 2005, 104 (04) : 781 - 787
12345